-
Mashup Score: 8
ACC Anywhere offers 100 credits per calendar year (Jan 1 – Dec. 31) and will automatically track the time you spend watching videos to make it EASY to claim credit. You may claim credit multiple times per year, up to a maximum of 100 credits, and your credit and watch time will reset each year on January 1. Joint Accreditation Statement In support of improving patient care, this activity has…
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1ACC Anywhere - Landing page - 2 year(s) ago
ACC Anywhere provides easy access to all of ACC’s video content in one location. You can easily search and browse presentations and watch Collections anytime, anywhere with on demand access. Collection Stump the Chump: The Hardest Congenital Case of My Life – A “March Matchup” Session Stump the Chump: The Hardest Congenital Case of My Life – A “March Matchup” Session Stump the Chump: The…
Source: accanywhere.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Get on demand access to #ACC23/#WCCardio session on "Navigating CV Care in Patients w/ #Cancer" & keep pace w/ major findings in the field! Purchase ACC Anywhere today & get 1 year access to live & virtual #ACCEd. Learn more: https://t.co/ZduofUwLSM #CardioOnc #CardioTwitter https://t.co/MLNqDnwkX3
-
-
Mashup Score: 0BIOVASC: Immediate Complete Revascularization Beneficial in ACS - 2 year(s) ago
Immediate complete revascularization during the index procedure might become the new treatment paradigm in patients with ACS and multivessel disease, results of the BIOVASC trial suggest.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Commenting on the BIOVASC trial at #ACC23/#WCCardio, #JACCINT Editor-in-Chief Dr. David Moliterno said the study poses the question “Can we fix it all at once?" and the results suggest "Yes, we can." Read more about the findings in @Medscape: https://t.co/FFgTmp0XJC
-
-
Mashup Score: 4STS/ACC TVT Registry Analysis Finds TMVr Safe and Effective in Real-World Setting - American College of Cardiology - 2 year(s) ago
Transcatheter edge-to-edge repair (TEER) in patients with degenerative mitral regurgitation (MR) was found to be safe with a close to 90% success rate, according to an analysis of STS/ACC TVT Registry data presented at ACC.23/WCC. In the largest study to examine outcomes of transcatheter mitral valve repair (TMVr) outside of the clinical trial setting, Raj R. Makkar, MD, FACC, et al., analyzed…
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Transcatheter edge-to-edge repair in patients w/ degenerative #vhdMR was found to be safe w/ a close to 90% success rate, according to an analysis of STS/ACC #TVTRegistry data. Read more: https://t.co/Efly2OK21I #NCDR #CardioOnc #ACC23 #WCCardio https://t.co/jNvu93kr1a
-
-
Mashup Score: 2
Anthony A. Bavry, MD, MPH, FACC
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: Results from the RENOVATE-COMPLEX-PCI trial, presented at #ACC23/#WCCardio, showed that intravascular imaging-guided #PCI improves outcomes by reducing target vessel failure. Read more: https://t.co/HNYU01NlnJ #CardioOnc #CardioTwitter https://t.co/Ljdg9GFSaU
-
-
Mashup Score: 4
Dharam J. Kumbhani, MD, SM, FACC
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: The goal of COAPT trial presented at #ACC23/#WCCardio was to assess the safety and efficacy of transcatheter mitral leaflet approximation using #MitraClip among symptomatic #heartfailure patients w/ secondary #vhdMR. Get more details: https://t.co/x5lHmmOnoI #CardioOnc https://t.co/X0csKYHDNe
-
-
Mashup Score: 0
Patients with ACS and multivessel disease saw multiple outcome benefits in BIOVASC trial
Source: www.medpagetoday.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#JACCINT Editor-in-Chief Dr. David Moliterno said the BIOVASC trial findings “reinforced the [revascularization] timing; that it can be done at the same time.” Read more about the #ACC23/#WCCardio trial in @medpagetoday: https://t.co/aWliieJMBU
-
-
Mashup Score: 0Sotatercept, Fixed-Dose Combo Therapy on the Right Path for PAH - 2 year(s) ago
More therapeutic options suggested by STELLAR, A DUE trials
Source: www.medpagetoday.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
According to 2 trials presented at #ACC23/#WCCardio, clinical evidence supports investigational compounds for addition to or simplification of frontline therapies for #cvPAH. #JACCHF Editor-in-Chief Dr. @biykemb commented on the findings. https://t.co/kXvV2QTYb6 @medpagetoday
-
-
Mashup Score: 1
For athletes and weekend warriors with HCM and LQTS, two new studies may offer a ray of hope.
Source: TCTMD.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
“Risk assessment, shared decision-making, close follow-up, emergency action plans are all important parts of care in the athlete,” #ACCSportsCardio Immediate Past Chair Dr. @eugenechung01 commented on 2 studies at #ACC23/#WCCardio. Read more: https://t.co/GQ3zBgM2Ft @TCTMD
-
-
Mashup Score: 0Wrist-worn sensor shows early promise for assessing likelihood of suspected heart attack - 2 year(s) ago
NEW ORLEANS — In a new study, use of a wrist-worn sensor was clinically feasible for rapid, bloodless prediction of elevated troponin I in patients with suspected MI, researchers reported at the American College of Cardiology Scientific Session.“Assessing high-sensitivity cardiac troponin for chest pain is standard practice in crowded emergency rooms. Although point-of-care tests are
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
According to a study at #ACC23/#WCCardio, use of a wrist-worn sensor showed promise for assessing the likelihood of suspected #cvMI. #ACCEP Chair @DrJCheungEP shares his perspective on the study in @CardiologyToday: https://t.co/eUMVK9VyGj @ScottBuzby
-
It's been a great educational weekend of learning during ACC's #CardioOnc course! Did you know #ACC23/#WCCardio attendees have access to ALL ACC Anywhere content, including Cardio-Onc presentations? Learn more & activate your account here: https://t.co/Cw8sibZUJl #ACCEd https://t.co/269gczFlvp